MET and non-small cell lung carcinoma: A molecular alteration in NSCLC is considered rare when it is present in very low incidence, such as in patients harboring ROS1 (1–2%), BRAF (1–3%), NTRK (3–4), HER 2 (3%), MET (3–4%) and RET (1%) [26].